Pascal Pfister

1.2k total citations
21 papers, 765 citations indexed

About

Pascal Pfister is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Immunology and Allergy. According to data from OpenAlex, Pascal Pfister has authored 21 papers receiving a total of 765 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 13 papers in Physiology and 3 papers in Immunology and Allergy. Recurrent topics in Pascal Pfister's work include Asthma and respiratory diseases (12 papers), Respiratory and Cough-Related Research (10 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers). Pascal Pfister is often cited by papers focused on Asthma and respiratory diseases (12 papers), Respiratory and Cough-Related Research (10 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers). Pascal Pfister collaborates with scholars based in Switzerland, Greece and United Kingdom. Pascal Pfister's co-authors include Κonstantinos Κostikas, Jean Bousquet, Xavier Jaumont, Marc Humbert, Francesco Patalano, Jadwiga A. Wedzicha, Stefan Frent, Donald Banerji, Robert Fogel and Kenneth R. Chapman and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, European Respiratory Journal and Molecular Pharmacology.

In The Last Decade

Pascal Pfister

21 papers receiving 745 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pascal Pfister Switzerland	13	519	494	109	62	61	21	765
Kartik Shenoy United States	11	200 0.4×	230 0.5×	50 0.5×	125 2.0×	24 0.4×	24	518
R Bhagat India	11	522 1.0×	425 0.9×	238 2.2×	72 1.2×	29 0.5×	19	761
Bapu Koundinya Desiraju India	10	92 0.2×	138 0.3×	8 0.1×	15 0.2×	48 0.8×	21	341
Byron A. Myhre United States	15	183 0.4×	54 0.1×	33 0.3×	55 0.9×	62 1.0×	59	718
H Klech Austria	12	303 0.6×	510 1.0×	17 0.2×	61 1.0×	80 1.3×	34	765
Benjamin Kendziora Germany	13	46 0.1×	105 0.2×	46 0.4×	14 0.2×	16 0.3×	35	481
Yao Xu China	11	179 0.3×	34 0.1×	50 0.5×	185 3.0×	96 1.6×	27	708
David Zhang United States	12	92 0.2×	292 0.6×	7 0.1×	38 0.6×	85 1.4×	30	567
Patricia Castillo United States	12	62 0.1×	137 0.3×	7 0.1×	91 1.5×	80 1.3×	31	613
Giacomo Malipiero Italy	12	104 0.2×	86 0.2×	39 0.4×	77 1.2×	26 0.4×	18	406

Countries citing papers authored by Pascal Pfister

Since Specialization

Citations

This map shows the geographic impact of Pascal Pfister's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pascal Pfister with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pascal Pfister more than expected).

Fields of papers citing papers by Pascal Pfister

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pascal Pfister. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pascal Pfister. The network helps show where Pascal Pfister may publish in the future.

Co-authorship network of co-authors of Pascal Pfister

This figure shows the co-authorship network connecting the top 25 collaborators of Pascal Pfister. A scholar is included among the top collaborators of Pascal Pfister based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pascal Pfister. Pascal Pfister is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hanania, Nicola A., Robert Niven, Pascal Chanez, et al.. (2022). Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma. World Allergy Organization Journal. 15(10). 100695–100695. 12 indexed citations

Price, David, Rupert Jones, Pascal Pfister, et al.. (2021). Maximizing Adherence and Gaining New Information For Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical Outcomes. PubMed. Volume 12. 25–35. 9 indexed citations

Bousquet, Jean, Marc Humbert, Peter G. Gibson, et al.. (2021). Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies. The Journal of Allergy and Clinical Immunology In Practice. 9(7). 2702–2714. 97 indexed citations

Kaplan, Alan, Hui Cao, J. Mark FitzGerald, et al.. (2021). Artificial Intelligence/Machine Learning in Respiratory Medicine and Potential Role in Asthma and COPD Diagnosis. The Journal of Allergy and Clinical Immunology In Practice. 9(6). 2255–2261. 128 indexed citations

Geßner, Christian, Oliver Kornmann, Jorge Máspero, et al.. (2020). Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON). Respiratory Medicine. 170. 106021–106021. 52 indexed citations

Kaplan, Alan, Hui Cao, J. Mark FitzGerald, et al.. (2020). Asthma/COPD Differentiation Classification (AC/DC): Machine Learning to Aid Physicians in Diagnosing Asthma, COPD and Asthma-COPD Overlap (ACO). A6285–A6285. 5 indexed citations

Κostikas, Κonstantinos, Alexander Mackay, Claus Vogelmeier, et al.. (2020). <p>Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients</p>. International Journal of COPD. Volume 15. 1831–1838. 3 indexed citations

Mackay, Alexander, Κonstantinos Κostikas, Nicolás Roche, et al.. (2020). Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study. Respiratory Research. 21(1). 93–93. 12 indexed citations

Κatsaounou, Paraskevi, Roland Buhl, Guy Brusselle, et al.. (2019). Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma. Respiratory Medicine. 150. 51–62. 24 indexed citations

10.

Humbert, Marc, Jean Bousquet, Claus Bachert, et al.. (2019). IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy. The Journal of Allergy and Clinical Immunology In Practice. 7(5). 1418–1429. 76 indexed citations

11.

López‐Abente, Jacobo, Cristina Benito‐Villalvilla, Xavier Jaumont, et al.. (2019). Late Breaking Abstract - IgE-FceR1 cross-linking impairs the capacity of plasmacytoid dendritic cells to induce in vitro functional regulatory T cells which can be restored by Omalizumab. OA3803–OA3803. 3 indexed citations

12.

Chapman, Kenneth R., John R. Hurst, Stefan Frent, et al.. (2018). Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial. American Journal of Respiratory and Critical Care Medicine. 198(3). 329–339. 171 indexed citations

13.

Κostikas, Κonstantinos, Alexander Mackay, Claus Vogelmeier, et al.. (2018). Early Clinically Important Improvement (ECII) and exacerbation outcomes in the FLAME study. OA1657–OA1657. 1 indexed citations

14.

Ferri, Nicola, Carlo Pirola, Francesca Torti, et al.. (2008). Fluvastatin Synergistically Improves the Antiproliferative Effect of Everolimus on Rat Smooth Muscle Cells by Altering p27 /Cyclin E Expression. Molecular Pharmacology. 74(1). 144–153. 15 indexed citations

15.

Hobbie, Sven N., Christian M. Bruell, Sarath K. Kalapala, et al.. (2006). A genetic model to investigate drug–target interactions at the ribosomal decoding site. Biochimie. 88(8). 1033–1043. 47 indexed citations

16.

Eliraz, A, Alicia Ramírez‐Rivera, G. Rapatz, et al.. (2001). SIMILAR EFFICACY FOLLOWING FOUR WEEKS TREATMENT OF ASTHMATICS WITH FORMOTEROL 12 μG B.D. DELIVERED BY TWO DIFFERENT DRY POWDER INHALERS: DIFFERENCES IN INHALER HANDLING. International Journal of Clinical Practice. 55(3). 164–170. 19 indexed citations

17.

Eliraz, A, Alicia Ramírez‐Rivera, Pietro Ferranti, et al.. (2001). Similar efficacy following four weeks treatment of asthmatics with formoterol 12 micrograms b.d. delivered by two different dry powder inhalers: differences in inhaler handling.. PubMed. 55(3). 164–70. 16 indexed citations

18.

Ratsitorahina, Maherisoa, et al.. (2000). [Estimation of normal hemogram values in Madagascar].. PubMed. 66(1-2). 68–71. 10 indexed citations

19.

Bouros, Demosthenes, John Kottakis, Pascal Pfister, et al.. (1999). Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. European Respiratory Journal. 14(3). 627–627. 41 indexed citations

20.

Lötvall, Jan, Á. Callejo Mellén, Peter Arvidsson, et al.. (1999). Similar Bronchodilation with Formoterol Delivered by Aerolizer or Turbuhaler. Canadian Respiratory Journal. 6(5). 412–416. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact